Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 87

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 87
---
:|:--|:----|:---------------|-----------:|:--|:----|:-----------|:-----------|:--|
| Net cash used in operating activities                             |     | $                    | (9,068,702 | ) |     | $              | (8,617,285 | ) |     | $          | (451,417   | ) |
| Net cash provided by                                              
 financing activities:                                             |     |                      |  9,044,316 |   |     |                |  9,748,916 |   |     |            | (704,600   | ) |
| Net                                                               
 (decrease) increase in cash, restricted cash and cash equivalents |     | $                    |    (24,386 | ) |     | $              |  1,131,631 |   |     | $          | (1,156,017 | ) |

Net cash used in operating activities

Net cash used in operating
activities for the six months ended June 30, 2025 primarily reflected a net loss of $10,523,000, adjusted for the reconciliation of non-cash
items such as depreciation expense of $146,000, stock-based compensation of $488,000, stock-based inducement expense of $864,000, and
amortization of right-of-use asset of $391,000, and changes in operating asset and liabilities primarily consisting of an increase in
prepaid expenses and other current assets of $169,000, an increase in accounts payable of $562,000, a decrease in accrued liabilities
of $404,000, and a decrease in operating lease liabilities of $423,000.

Net cash used in operating activities for the six months ended June
30, 2024 primarily reflected a net loss of $4,748,000, adjusted for the reconciliation of non-cash items such as a gain of settlement
of liabilities with vendors of $589,000, depreciation expense of $228,000, stock-based compensation of $1,489,000, amortization of right-of-use
asset of $353,000 and a gain on revaluation of earnout liability and the preferred stock warrant liability of $5,020,000, and changes
in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $269,000, a decrease
in accounts payable of $551,000, an increase in accrued liabilities of $941,000,